Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

COVID-19 – Update

Update from Sygnature Group following the PM’s announcement

Following the announcement from Boris Johnson, the Prime Minister of the United Kingdom on the evening of Monday 23rd March 2020 we felt it would be helpful to give an update from Sygnature Group, comprising Sygnature Discovery and RenaSci.

In the PM’s statement, the guidance specifies that people will only be allowed to leave their home for very limited purposes, including travelling to and from work where this is absolutely necessary and when the work cannot be done from home.

Sygnature Group is responding to the COVID-19 situation in a manner that we believe is both in-line with current UK government guidance and supportive of our employees and customers. We continue to monitor the situation closely and are responsive to any further changes in this dynamic situation.

The safety and well-being of our colleagues in Sygnature Group is of critical importance to us and we have taken heed of the new advice issued from the UK government. We are managing the current unprecedented situation by having as many of our employees as possible working from home, and where that is not possible, we have now put in place flexible work patterns that are helping to reduce the number of people in the same location at the same time. We have minimised face to face meetings as well as other gatherings in the workplace.

Sygnature Group is delighted by the excellent levels of support from our teams in successfully managing this situation and ensuring all projects are up and running. We are thankful that we are able to continue our revised operating procedures that help protect our staff while continuing to serve our customers without disruption.

If you have any questions about your projects or working with Sygnature Discovery or RenaSci during these unprecedented times, then please contact us via any of the contact form

Latest News

View All

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.